Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial

被引:46
作者
Zhu, L
Chow, LWC
Loo, WTY
Guan, XY
Toi, M
机构
[1] Univ Hong Kong, Hung Chao Hong Integrated Ctr Breast Dis, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[3] Tokyo Metropolitan Komagome Hosp, Breast Unit, Dept Surg, Tokyo, Japan
关键词
D O I
10.1158/1078-0432.CCR-04-0057
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Many studies suggest that Her2/neu play an important role in neoadjuvant endocrine therapy. This study aimed to determine whether the level of Her2/neu expression in advanced breast cancer changes after antiaromatase neoadjuvant treatment, as well as to identify the relationship between Her2/neu expression and response to this kind of therapy. Experimental Design: Thirty-six postmenopausal patients with hormonal receptor-positive primary breast cancer were included in a study of three monthly cycles of neoadjuvant endocrine therapy with either Aromasin (25 mg daily) or Femara (2.5 mg daily). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for Her2/neu were conducted both on pretreatment biopsies and surgical tumors. Results: Using HIC, 5 of 36 (13.9%) of the patients had a Her2/neu overexpression after treatment, as compared with 16 of 36 (44.4%) before. Meanwhile, there was no change in 21 (58.3%) patients, and through FISH, there was a change from amplification to no amplification in 15 (41.7%) patients. The response rate to the treatment was 75% for Her2/neu (+) tumors and 35% for Her2/neu (-) tumors (P = 0.017) while FISH was performed. The response rate was also significantly affected by the decrease in Her2/neu status after the treatment, with 73% of the tumors showing decreased Her2/neu expression and with 38 % of the tumors showing no change of Her2/neu expression (P 0.037). Conclusions: Using both HIC and FISH, advanced breast cancers show statistical evidence of decreasing incidence of Her2/neu expression after antiaromatase neoadjuvant treatment. Our data also suggest that Her2/neu expression and its change during the treatment might be predictive markers for this kind of therapy.
引用
收藏
页码:4639 / 4644
页数:6
相关论文
共 43 条
  • [1] EXPRESSION OF RAS P21, P53 AND C-ERBB-2 IN ADVANCED BREAST-CANCER AND RESPONSE TO FIRST LINE HORMONAL-THERAPY
    ARCHER, SG
    ELIOPOULOS, A
    SPANDIDOS, D
    BARNES, D
    ELLIS, IO
    BLAMEY, RW
    NICHOLSON, RI
    ROBERTSON, JFR
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (05) : 1259 - 1266
  • [2] ESTROGEN-DEPENDENT, TAMOXIFEN-RESISTANT TUMORIGENIC GROWTH OF MCF-7 CELLS TRANSFECTED WITH HER2/NEU
    BENZ, CC
    SCOTT, GK
    SARUP, JC
    JOHNSON, RM
    TRIPATHY, D
    CORONADO, E
    SHEPARD, HM
    OSBORNE, CK
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1992, 24 (02) : 85 - 95
  • [3] ONCOGENE AMPLIFICATION AND PROGNOSIS IN BREAST-CANCER - RELATIONSHIP WITH SYSTEMIC TREATMENT
    BERNS, EMJJ
    FOEKENS, JA
    VANSTAVEREN, IL
    VANPUTTEN, WLJ
    DEKONING, HYWCM
    PORTENGEN, H
    KLIJN, JGM
    [J]. GENE, 1995, 159 (01) : 11 - 18
  • [4] BIANCO AR, 1998, P AN M AM SOC CLIN, V17, P97
  • [5] Current perspectives on HER2 testing:: A review of national testing guidelines
    Bilous, M
    Dowsett, M
    Hanna, W
    Isola, J
    Lebeau, A
    Moreno, A
    Penault-Llorca, F
    Rüschoff, J
    Tomasic, G
    de Vijver, MV
    [J]. MODERN PATHOLOGY, 2003, 16 (02) : 173 - 182
  • [6] Birner P, 2001, CLIN CANCER RES, V7, P1669
  • [7] PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE
    BONADONNA, G
    VERONESI, U
    BRAMBILLA, C
    FERRARI, L
    LUINI, A
    GRECO, M
    BARTOLI, C
    DEYOLDI, GC
    ZUCALI, R
    RILKE, F
    ANDREOLA, S
    SILVESTRINI, R
    DIFRONZO, G
    VALAGUSSA, P
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) : 1539 - 1545
  • [8] c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
    Carlomagno, C
    Perrone, F
    Gallo, C
    DeLaurentiis, M
    Lauria, R
    Morabito, A
    Pettinato, G
    Panico, L
    DAntonio, A
    Bianco, AR
    DePlacido, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2702 - 2708
  • [9] Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report
    Chow, LWC
    Wong, JLN
    Toi, M
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 86 (3-5) : 443 - 447
  • [10] THE NEU-PROTEIN AND BREAST-CANCER
    DEPOTTER, CR
    SCHELFHOUT, AM
    [J]. VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY, 1995, 426 (02): : 107 - 115